Brentuximab Vedotin and Nivolumab in Treating Participants With Early Stage Classic Hodgkin Lymphoma



Status:Recruiting
Conditions:Lymphoma, Neurology
Therapuetic Areas:Neurology, Oncology
Healthy:No
Age Range:16 - Any
Updated:1/17/2019
Start Date:November 28, 2018
End Date:November 2020

Use our guide to learn which trials are right for you!

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

This phase II trial studies how well brentuximab vedotin and nivolumab work in treating
participants with stage I-II classic Hodgkin lymphoma. Monoclonal antibodies, such as
brentuximab vedotin and nivolumab, may interfere with the ability of tumor cells to grow and
spread.

PRIMARY OBJECTIVES:

I. Determine the 18 month progression free survival (PFS) for each arm of therapy stratified
by positron emission tomography (PET)/computed tomography (CT)-2 response.

SECONDARY OBJECTIVES:

I. Assess safety, tolerability, and quality of life (QOL) for each arm of therapy.

II. Measure PET/CT-2 negativity rate after 2 lead-in cycles of doxorubicin, bleomycin,
vinblastine, dacarbazine (ABVD).

III. Evaluate the 3-year PFS and overall survival (OS) for each arm of treatment.

EXPLORATORY OBJECTIVES:

I. Evaluate if a baseline antitumor immune response, as assessed by a Nanostring gene panel,
correlates with PFS.

II. Evaluate if minimal residual disease (MRD) status, as monitored by cancer personalized
profiling by deep sequencing (CAPP-Seq) of circulating tumor (ct) deoxyribonucleic acid
(DNA), can be correlated with PFS.

OUTLINE: Participants are assigned to 1 of 2 groups based on their PET/CT-2 scans.

GROUP I (PET/CT-2 NEGATIVE): Participants without bulky disease are randomized to either Arm
A or B and participants with bulky disease are assigned to Arm B.

ARM A: Participants receive brentuximab vedotin intravenously (IV) over 30 minutes and
nivolumab IV over 60 minutes on day 1. Treatment repeat every 21 days for up to 3 courses in
the absence of disease progression or unacceptable toxicity.

ARM B: Participants receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on
days 1 and 15. Treatment repeats every 28 days for up to 2 courses in the absence of disease
progression or unacceptable toxicity. Participants then receive nivolumab IV over 60 minutes
on day 1. Treatment with nivolumab repeats every 14 days for up to 6 courses in the absence
of disease progression or unacceptable toxicity.

GROUP II (PET/CT-2 POSITIVE): Participants receive doxorubicin IV, vinblastine IV,
dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment
repeats every 28 days for up to 4 courses in the absence of disease progression or
unacceptable toxicity. Participants that are PET/CT negative receive nivolumab IV over 60
minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 courses in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up for 3 years.

Inclusion Criteria:

- Documented informed consent of the participant and/or legally authorized
representative.

- Assent, when appropriate, will be obtained per institutional guidelines.

- Eastern Cooperative Oncology Group (ECOG) =< 2.

- Histologically confirmed diagnosis of classical Hodgkin lymphoma (cHL) by current
World Health Organization classification (nodular sclerosis, mixed cellularity,
lymphocyte rich, lymphocyte depleted, or classical Hodgkin lymphoma, NOS [not
otherwise specified]) at local enrolling center.

- Stage IA, IB, IIA, or IIB cHL by Cotswold modified Ann Arbor staging done prior to any
treatment with ABVD.

- Ability to document transverse diameter in cm of largest mediastinal mass and
favorable versus unfavorable risk factor criteria as determined by German Hodgkin
Study Group (GHSG) criteria at baseline prior to ABVD treatment.

- Must have at baseline prior to ABVD treatment at least one lesion that is > 1.5 cm in
the longest diameter on cross-sectional imaging and measureable in two perpendicular
dimensions on CT and fludeoxyglucose (FDG) avid by PET.

- Absolute neutrophil count (ANC) >= 1,000/mm^3.

- Platelets >= 75,000/mm^3.

- Hemoglobin >= 8 g/dL.

- Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless the elevation is known to
be related to Gilbert's syndrome).

- Aspartate aminotransferase (AST) =< 2.5 x ULN.

- Alanine aminotransferase (ALT) =< 2.5 x ULN.

- Creatinine clearance >= 30 mL/min per 24 hour urine collection or the Cockcroft-Gault
formula.

- Left ventricular ejection fraction (LVEF) >= 45%.

- Carbon monoxide diffusion capacity (DLCO) (adjusted for hemoglobin [Hb]) >= 60%.

- Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If
the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
will be required.

- Agreement by females and males of childbearing potential to use an effective method of
birth control or abstain from heterosexual activity for the course of the study
through at least 6 months after the last dose of protocol therapy.

- Childbearing potential defined as not being surgically sterilized (men and women)
or have not been free from menses for > 1 year (women only).

Exclusion Criteria:

- Patients must be naive in terms of any prior therapy for Hodgkin lymphoma (including
immunotherapy, chemotherapy or radiation therapy) with the exception that they may
have received up to 2 cycles of ABVD as standard of care therapy prior to enrollment,
as long as they can start subsequent therapy (therapy administered in Arms A, B1/B2,
or C) within timelines specified by the trial.

- Subjects with a non-lymphoma related condition requiring systemic treatment with
either corticosteroids (> 10 mg daily prednisone equivalents) or other
immunosuppressive medications within 14 days of study drugs administration. Patients
can have received short term dosing of steroids prior to the start of ABVD
chemotherapy for management of symptoms of cHL and any steroids given for cHL symptom
management should be tapered down to 10 mg or less of prednisone equivalents by the
time of start of ABVD chemotherapy, and fully tapered off by week 1 of ABVD.

- Sensory > grade 1 or any peripheral motor neuropathy.

- History of another primary malignancy that has not been in remission for at least 3
years. (The following are exempt from the 3-year limit: nonmelanoma skin cancer, fully
excised melanoma in situ [Stage 0], curatively treated localized prostate cancer, and
cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on
Papanicolaou [PAP] smear)

- Known cerebral/meningeal disease.

- History of progressive multifocal leukoencephalopathy (PML).

- Known history of pancreatitis.

- Documented history of a cerebral vascular event (stroke or transient ischemic attack),
unstable angina, myocardial infarction, or cardiac symptoms consistent with New York
Heart Association class III-IV within 6 months prior to their first dose of study
drug(s).

- Uncontrolled cardiac disease including ventricular dysfunction, left ventricular
ejection fraction < 45%, coronary artery disease, or arrhythmias.

- Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient
contained in the drug formulation of brentuximab vedotin, nivolumab, or any component
of ABVD.

- Known active infection with hepatitis B or hepatitis C. Patients who are hepatitis B
carriers can enroll if have a negative hepatitis B polymerase chain reaction (PCR) DNA
test and are on hepatitis B suppressive medication management with entecavir or
lamivudine. Patients with past active hepatitis C virus (HCV) infection are eligible
if they are PCR negative after curative therapy. Testing to be done only in patients
suspected of having infections or exposures.

- Known active infection with human immunodeficiency virus (HIV). Patients who are HIV
positive can enroll if CD4 count is > 200/uL and have an undetectable HIV viral load
within 28 days of enrollment, have concurrent management with infectious disease
specialists, and are on stable combination antiretroviral therapy. Participants are
required to be on antiretroviral regimens that are in accordance with the current
International acquired immune deficiency syndrome (AIDS) Society guidelines
concurrently with chemotherapy. The specific agents are at the discretion of the
Investigator and the use of investigational agents currently available on an expanded
access basis is allowed. Use of experimental antiretroviral agents or those containing
zidovudine (including Combivir and Trizivir) or ritonavir (includes Norvir or
Kaletra), Cobicistat, Didanosine (Videx or Videx EC), or similar potent CYP3
inhibitors are prohibited. In order to be eligible, participants taking zidovudine or
ritonavir, Cobicistat, Didanosine, or other CYP3 inhibitors must change to a different
regimen 7 days prior to therapy initiation. Changes to highly active antiretroviral
therapy (HAART) therapy during the study may be made if medically necessary (toxicity,
failure of regimen, etc.). Participants must be on HAART for at least 7 days prior to
therapy.

- Any active systemic viral, bacterial, or fungal infection requiring treatment with IV
antimicrobial therapy within 1 week prior to enrollment.

- Subjects with active interstitial pneumonitis.

- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,
type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only
requiring hormone replacement, psoriasis not requiring systemic treatment, or
conditions not expected to recur in the absence of an external trigger are permitted
to enroll.

- Females only: pregnant or breastfeeding.

- Any other condition that would, in the investigator's judgment, contraindicate the
patient's participation in the clinical study due to safety concerns with clinical
study procedures.

- Prospective participants who, in the opinion of the investigator, may not be able to
comply with all study procedures (including compliance issues related to
feasibility/logistics).
We found this trial at
29
sites
Duarte, California 91010
Principal Investigator: Alex Herrera, MD
Phone: 626-256-4673
?
mi
from
Duarte, CA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Andy I. Chen, MD, PhD
Phone: 503-494-5058
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Carla Casulo, MD
Phone: 585-275-5823
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Kristie A. Blum, MD
Phone: 404-778-1900
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Andres Forero-Torres, MD
Phone: 205-934-7167
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Ann S. LaCasce, MD
Phone: 617-632-5959
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charlestown, Massachusetts 02129
Principal Investigator: Jeremy S. Abramson, MD
Phone: 617-724-4000
?
mi
from
Charlestown, MA
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Steven I. Park, MD
Phone: 704-403-1370
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Jane N. Winter, MD
Phone: 312-695-4538
?
mi
from
Chicago, IL
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Sonali M. Smith, MD
Phone: 773-834-2895
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cleveland, Ohio 44195
Principal Investigator: Deepa Jagadeesh, MD
Phone: 216-444-0857
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Denver, Colorado 80210
Principal Investigator: Manali K. Kamdar, MD
Phone: 720-848-3389
?
mi
from
Denver, CO
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Jeffrey V. Matous, MD
Phone: 720-754-4800
?
mi
from
Denver, CO
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Radhakrishnan Ramchandren, MD
Phone: 800-527-6266
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Tatyana A. Feldman, MD
Phone: 201-996-3033
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: John M. Timmerman, MD
Phone: 310-829-5471
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
230 25th Ave N
Nashville, Tennessee 37203
(615) 329-7274
Principal Investigator: Ian W. Flinn, MD, PhD
Phone: 205-934-7167
Sarah Cannon Cancer Center People who live with cancer
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Catherine S. Diefenbach, MD
Phone: 404-778-1900
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Alison J. Moskowitz, MD
Phone: 212-639-4839
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
445 E 69th St
New York, New York 10021
(212) 746-1067
Principal Investigator: Peter Martin, MD
Phone: 646-962-2064
Weill Medical College of Cornell University Founded in 1898, and affiliated with what is now...
?
mi
from
New York, NY
Click here to add this to my saved trials
875 Blake Wilbur Drive
Palo Alto, California 94304
Principal Investigator: Ranjana H. Advani, MD
Phone: 650-498-6000
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Jakub Svoboda, MD
Phone: 215-615-5858
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Stephen M. Ansell, MD, PhD
Phone: 507-284-2511
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Nancy L. Bartlett, MD
Phone: 314-362-5654
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
2000 Circle of Hope Dr
Salt Lake City, Utah 84112
(801) 585-0303
Principal Investigator: Martha J. Glenn, MD
Phone: 801-585-0134
Huntsman Cancer Institute at University of Utah Huntsman Cancer Institute (HCI) is part of the...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Diego, California 92093
Principal Investigator: Carolyn M. Mulroney, MD
Phone: 858-822-6600
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Seattle, Washington 98109
Principal Investigator: Ajay K. Gopal, MD
Phone: 206-288-1000
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tucson, Arizona 85724
Principal Investigator: Daniel O. Persky, MD
Phone: 520-694-0111
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Vancouver, British Columbia
Principal Investigator: Kerry J. Savage, MD
Phone: 604-877-6000
?
mi
from
Vancouver,
Click here to add this to my saved trials